The authors selected SM04690 by screening a library of compounds for 49 their capacity to suppress canonical WNT signaling in cell lines, and 50 subsequently in primary chondrocytes. Non-canonical WNT pathways, which 51 also affect cartilage biology 10 were likely unaffected, at least based on regulation 52 of target genes. 53 As expected of a WNT antagonist, SM04690 supported chondrogenic 54 differentiation of mesenchymal stem cells in vitro with an EC50 at the low 55 nanomolar range. Less predictably, they also showed that SM04690 has also 56 anti-catabolic properties in that it inhibited cartilage extracellular matrix 57 breakdown and suppressed the expression of catabolic metalloproteinases. 58
In vivo, a single intraarticular injection of 0. 
